Trial Profile
Effect of pomalidomide on immune modulation at the time of early lymphocyte recovery in patients with AML
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2019
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Cytarabine; Daunorubicin; Etoposide
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Pharmacodynamics
- 04 Dec 2018 Results (n=51) assessing Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy for Acute Myeloid Leukemia and High-Risk Myelodysplasia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 22 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology